ARCTURUS THERAPEUTICS HOLDINGS INC. Form 8-K (Dec. 7, 2021)

Summary

Current report on Form 8-K of Arcturus Therapeutics Holdings Inc., date of report December 7, 2021, filed under Items 5.02, 5.05, 7.01 and 9.01. It states that on December 7, 2021 the Board of Directors, on the recommendation of the Nominating and Governance Committee, appointed Dr. Jing Marantz as a director until the next annual meeting of stockholders. Dr. Marantz is Senior Vice President, Head of Medical Affairs of Acceleron Pharma, Inc. since October 2020, and was Senior Vice President, Medical Affairs of Alnylam Pharmaceuticals, Inc. from June 2018 to September 2020. The Board also adopted a new Code of Business Conduct and Ethics on December 7, 2021, filed as Exhibit 14.1. The signature block shows /s/ Joseph E. Payne, dated December 13, 2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 7, 2021

ARCTURUS THERAPEUTICS HOLDINGS INC.

(Exact name of registrant as specified in its
charter)

Delaware | 001-38942 | 32-0595345
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.)

10628 Science Center Drive , Suite 250

San Diego , California 92121

(Address of principal executive offices)

Registrant’s telephone number, including
area code: (858) 900-2660

(Former name or former address, if changed since
last report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common stock, par value $0.001 per share | ARCT | The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐

Item 5.02. | Departure of Directors or Certain Officers;
 Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 7, 2021, the Nominating and Governance
Committee (the “ Committee ”) of the Board of Directors (the “ Board ”) of Arcturus Therapeutics Holdings
Inc. (the “ Company ”) recommended the appointment of, and the Board subsequently appointed, Dr. Jing Marantz to serve
as a director of the Company, effective as of December 7, 2021 until the Company’s next annual meeting of stockholders or until
Dr. Marantz’s successor is duly elected and qualified. There is no arrangement or understanding between Dr. Marantz and any other
person pursuant to which Dr. Marantz was selected as a director of the Company and there is no family relationship between Dr. Marantz
and any of the Company’s directors or executive officers. The Company is not aware of any transaction involving Dr. Marantz which
would require disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Act of 1933, as amended (the “ Securities
Act ”). Dr. Marantz will receive compensation similar to the other non-employee members of the Board as described in the
Company's Proxy Statement for the 2021 Annual Meeting of Stockholders as filed with the Securities and Exchange Commission on April 30,
2021.

Jing L. Marantz, M.D., Ph.D., MBA, age 56, has
served as Senior Vice President, Head of Medical Affairs of Acceleron Pharma, Inc. a clinical stage biopharmaceutical company (“ Acceleron ”),
since October 2020; in November 2021, Acceleron was acquired by and became a subsidiary of Merck Sharp & Dohme Corp. From June 2018
to September 2020, Dr. Marantz served as Senior Vice President, Medical Affairs of Alnylam Pharmaceuticals, Inc., a biopharmaceutical
company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases.
She served as Vice President, Global Medical Affairs for Alexion Pharmaceuticals from August 2016 to June 2018 and as Global Medical Lead
for TECFIDERA ® at Biogen from April 2014 to June 2016. Dr. Marantz earned her medical degree from Tongji Medical
College, Ph.D. in Biochemistry and Molecular Biology from Medical University of South Carolina and MBA from the University of California
at Berkeley.

Item 5.05. | Amendments to the Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics.

On December 7, 2021, the Board approved and adopted a new Code of
Business Conduct and Ethics (the “New Code of Conduct”). The New Code of Conduct is applicable to all directors, officers
and employees of the Company and its subsidiaries, including but not limited to the Company’s principal executive officer and principal
financial officer. The New Code of Conduct replaces the Company’s previous Code of Business Conduct and Ethics (the “ Prior
Code ”) in its entirety, to reflect current industry and public company best practices. The adoption by the Board of the New
Code of Conduct did not result in any explicit or implicit waiver with respect to any director, officer or employee of the Company from
any provision of the Prior Code. The New Code of Conduct became effective as of the date of the Board meeting approving the New Code of Conduct.

The description of the New Code of Conduct contained in this report
is qualified in its entirety by reference to the full text of the New Code of Conduct filed as Exhibit 14.1 to this Current Report on
Form 8-K. A copy of the New Code of Conduct is available on the Company’s website at www.arcturusrx.com, under the “Governance
Documents” section of the “Corporate Governance” tab, located in the "Investors Relations" portion of the
Company website.

Item 7.01. | Regulation FD Disclosure.

On December 13, 2021, the Company issued a press release, a copy of
which is filed herewith as Exhibit 99.1, announcing the appointment of Dr. Marantz. The information set forth in this Item 7.01 and
in Exhibit 99.1 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of that Section. The information in
this Item 7.01 and in Exhibit 99.1 shall not be deemed to be incorporated by reference into any filing of the Company under the Securities
Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference
in such a filing.

Item 9.01. | Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. | Description of Exhibit
14.1 | Arcturus Therapeutics Holdings Inc. Code of Conduct and Ethics
99.1 | Press Release, dated December 13, 2021, issued by Arcturus Therapeutics Holdings Inc.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Arcturus Therapeutics Holdings Inc.
Date: December 13, 2021
By: | /s/ Joseph E. Payne
Name: | Joseph E. Payne
Title: | Chief Executive Officer

File and source

File

SEC_ARCT_8-K_filed2021-12-13_0001193805-21-001738.htm

Size

29,109 bytes

SHA-256

3f64a94a6441e5bbaa34bef75c4861be543d732bdeb55452e469e1f2c152e41d

Our copy

SEC_ARCT_8-K_filed2021-12-13_0001193805-21-001738.htm

Original

www.sec.gov